Largest remote health monitoring project in the world launched in China

April 23, 2017

The IDEAL LIFE system is unique in its capability to provide two-way communication between the patient and the provider or health coach within the monitoring device, eliminating the need for expensive additional devices. The self-service kiosks allow unlimited users to connect with providers at reduced connectivity charges, giving entire communities unprecedented access to healthcare and to two-way educational communication at the point of care. These ingenious end-to-end solutions make IDEAL LIFE the most affordable system on the market. IDEAL LIFE's products also automatically populate and integrate seamlessly with the provider's data collection systems and with electronic medical records, so that this vital data can be accessed at any time and at any location.

China, the world's most populous country, faces the challenges of both Western countries and Third World nations in providing access to quality healthcare to its citizens, including a growing number of individuals with chronic illnesses.

The British medical journal "The Lancet" reports that approximately 153 million Chinese adults have hypertension; only 24 percent of these individuals are aware of their condition and less than 24 percent of that group have their blood pressure under control. According to the "New England Journal of Medicine," approximately 92.4 million adults in China have diabetes, almost twice as many as had been previously estimated. An estimated 50 million more Chinese with undiagnosed diabetes will enter medical care within the next 10 - 20 years, per a study just released by the International Diabetes Federation and the Chinese Diabetes Society. Finally, annual cardiovascular events in China are expected to increase 50 percent between 2010 and 2030 due to population aging and growth alone, as reported in "Future Cardiovascular Disease in China," published in "Circulation: Cardiovascular Quality and Outcomes."

Programs like the collaboration between IDEAL LIFE and NovaTech Biological Pharmaceutical Co., Ltd., are critically needed to cost-effectively manage these populations.